Drugs / I004
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07560150 | Apr → Jun 2026 overdue | — | Amphastar Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05539872 | Aug 2022 → Jan 2023 | — | Amphastar Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | I004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07560150 ↗ |
| Modality | Protein / enzyme biologic | “Insulin Aspart, a rapid-acting human insulin analogue” NCT05539872 ↗ |
| Route | Subcutaneous | “Drug will be administered via subcutaneous injection into the abdominal wall” NCT05539872 ↗ |